| History of plasma-product safety. | |
| | |
MedLine Citation:
|
PMID: 11441415 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The evolution of transfusion or infusion therapies for diseases requiring specific protein replacements (e.g., hemophilia A and B and severe combined immunodeficiency syndrome) was dramatic over the second half of the 20th century. Unfortunately, it was accompanied by extreme manifestations of transfusion-transmitted diseases, such as human immunodeficiency virus (HIV), hepatitis B, and hepatitis C. The milestones of both the replacement therapies and the associated diseases are discussed in this presentation, which focuses on the technologic advances that resulted in even more "pure" replacement therapies for plasma-protein diseases. From donor screening to the development of viral attenuation techniques, every facet of production for these products was impacted by the exigent push for viral safety created by HIV and hepatitis. Almost invariably, this negatively affects total product yield. At the beginning of the 21st century, success in making plasma products safe from recognized and potential pathogens has dramatically increased societal pressures to produce a zero-risk, plasma-derived protein therapy. However, past improvements and low theoretic risks for future pathogen contamination have increased product cost. This is associated with a possible decrease in the overall supply of these plasma proteins because of the reduced numbers of acceptable donors and the loss of protein from expanded attenuation technology. These impacts and the role of dynamic societal and scientific pressures on these decision processes are discussed. |
| | |
Authors:
|
W K Hoots |
Related Documents
:
|
14979275 - Us: hospital negligent for failing to warn prior patient of risk of hiv infection by tr... 10392725 - High prevalence and phylogenetic analysis of tt-virus infection in mongolia. 11920825 - Novel ttv variants isolated in an epidemic of hepatitis of unknown etiology. 7522025 - Epidemiology of hepatitis c virus in europe. 12410805 - Analysis of complement-bound hcv complexes using a novel immuno-capture rt-pcr method. 11251305 - Clinical, virological, immunological, and pathological significance of gb virus c/hepat... |
Publication Detail:
|
Type: Historical Article; Journal Article; Review |
Journal Detail:
|
Title: Transfusion medicine reviews Volume: 15 ISSN: 0887-7963 ISO Abbreviation: Transfus Med Rev Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-07-06 Completed Date: 2001-12-13 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 8709027 Medline TA: Transfus Med Rev Country: United States |
Other Details:
|
Languages: eng Pagination: 3-10 Citation Subset: IM |
Copyright Information:
|
Copyright 2001 by W.B. Saunders Company. |
Affiliation:
|
Houston Health Science Center and the MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Component Transfusion / history*, standards* Consumer Product Safety History, 20th Century History, 21st Century Humans Plasma / chemistry, microbiology* Sterilization / economics, history, standards |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Next Document: Safety issues affecting hemophilia products.